Please login to the form below
ViroPharma
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of ViroPharma's 2013 immunology sales performance.
Nabriva Therapeutics appoints chief medical officer
Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
Merck says drug for CMV in transplant patients hits targets
phase III testing that it acquired along with ViroPharma in 2013.
FDA grants fast track designation to Shire’s Cinryze
At the end of 2013, Shire signed a deal with US company Viropharma for around $4.2bn which gave the company rights to Cinryze.
Pharma deals in August 2015
indication]. Interestingly, the right to make the Meritage acquisition came via the purchase of ViroPharma.
Medius Deal Watch table for February 2015
Turkey. † US. †† Financial details source - Viropharma's 2013 Consolidated Financial Statement. .
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
CEO, Head of Health, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Valneva COVID-19 vaccine more effective than AZ
- US demand for COVID-19 antibody treatments rising fast
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- Towards Better HCP Engagement – An Email Masterclass
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- The Future of eHealth: Contactless Health Monitoring
- NICE looks internally for new chief executive
- Alex Butler and Matt Baker launch Foundry3
PMHub
Spirit, an OPEN Health Company
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
